Generate Biomedicines (NASDAQ:GENB) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a report issued on Tuesday morning, MarketBeat.com reports. The brokerage issued an overweight rating on the stock.

Separately, Wall Street Zen raised Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Generate Biomedicines presently has an average rating of “Buy” and an average target price of $25.00.

Generate Biomedicines Price Performance

Shares of Generate Biomedicines stock opened at $12.03 on Tuesday. Generate Biomedicines has a one year low of $11.00 and a one year high of $15.32.

Key Stories Impacting Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $24 price target (roughly +99% vs current levels). Benzinga
• Positive Sentiment: Morgan Stanley started coverage with an “overweight” and $20 price target (~+66%). Benzinga TickerReport
• Positive Sentiment: Goldman Sachs initiated with a “buy” and a $26 price target (~+116%). Benzinga
• Positive Sentiment: Guggenheim initiated coverage with a “buy” and a $30 price target (~+149%). Benzinga
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” rating. Benzinga
• Neutral Sentiment: Short-interest entries for late March show reported increases, but the published figures contain zeros and NaN values (short interest = 0 shares; days-to-cover = NaN), indicating data errors or unreliable reporting — treat these headlines as ambiguous until corrected by exchanges or the data provider.
• Neutral Sentiment: Trading volume is below average today (intraday volume lower than the 12-month average), which can amplify price moves and increase volatility on mixed news.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.